|
【结 构 式】 
|
【药物名称】Tozasertib, VX-680，MK-0457 【化学名称】N-[4-[4-(4-Methylpiperazin-1-yl)-6-(3-methyl-1H-pyrazol-5-ylamino)pyrimidin-2-ylsulfanyl]phenyl]cyclopropanecarboxamide 【CA登记号】639089-54-6 【 分 子 式 】C23H28N8OS 【 分 子 量 】464.5877 |
【开发单位】Vertex Pharmaceuticals, Inc. (US); developed in collaboration with Merck & Co. (US). 【药理作用】Aurora kinase inhibitor, Oncolytic |
合成路线1
The oxidation of 4,6-dichloro-2-(methylsulfanyl)pyrimidine (I) with MCPBA in dichloromethane gives 4,6-dichloro-2-(methylsulfonyl)pyrimidine (II), which is condensed with N-(4-sulfanylphenyl)cyclopropanecarboxamide (III) in hot butanol to yield the diaryl thioether (IV). The reaction of (IV) with 3-methyl-1H-pyrazol-5-amine (V) by means of DIEA in hot DMF affords the secondary amine (VI), which is finally condensed with 1-methylpiperazine (VII) by heating at 110 ºC to provide the target compound (1). Scheme 1.
| 【1】 Charrier, J.-D., Kay, D., Mazzei, F., Miller, A. (Vertex Pharmaceuticals, Inc.). Processes for preparing substd. pyrimidines and pyrimidine derivs. as inhibitors of protein kinase. EP 1517905, EP 1746093, JP 2005320351, JP 2006501176, US 2004049032, WO 2004000833. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 65246 | 4,6-Dichloro-2-(methylthio)pyrimidine；4,6-dichloro-2-(methylsulfanyl)pyrimidine | 6299-25-8 | C5H4Cl2N2S | 详情 | 详情 |
| (II) | 65247 | 4,6-Dichloro-2-(methylsulfonyl)pyrimidine; 2-(Methylsulfonyl)-4,6-Dichloropyrimidine; NSC 45040 | 4489-34-3 | C5H4Cl2N2O2S | 详情 | 详情 |
| (III) | 65248 | N-(4-mercaptophenyl)cyclopropanecarboxamide | 639090-54-3 | C10H11NOS | 详情 | 详情 |
| (IV) | 65249 | C13H11Cl2N3OS | 详情 | 详情 | ||
| (V) | 65250 | 5-amino-3-methyl-1H-pyrazole | C4H7N3 | 详情 | 详情 | |
| (VI) | 65251 | C17H17ClN6OS | 详情 | 详情 | ||
| (VII) | 10061 | 1-Methylpiperazine; 1-Methyl piperazine; N-Methylpiperazine | 109-01-3 | C5H12N2 | 详情 | 详情 |